

Please type a plus sign (+) inside this box → 

①-27-03

PTO/SB/29 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CONTINUED PROSECUTION APPLICATION (CPA)  
REQUEST TRANSMITTALSubmit an original, and a duplicate for fee processing.  
(Only for Continuation or Divisional applications under 37 CFR 1.53(d)) CHECK BOX, if applicable.  
DUPLICATE

ADDRESS TO:  Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No. Of Prior Application	THUR-001
	First Named Inventor	HOFFMAN, KEITH B.
	Examiner Name	TRAVERS, RUSSELL S.
	Group Art Unit	1617
	Express Mail Label No.	EL779660148US

This is a request for a  continuation or  divisional application under 37 CFR 1.53(d),  
(continued prosecution application (CPA)) of prior application number 09/582,964 filed on July 6, 2000, entitled:  
**THE USE OF SERINE PROTEASE INHIBITORS TO INHIBIT PATHOPHYSIOLOGY AND NEUROPATHOLOGY IN A HOST**

## NOTES

**FILING QUALIFICATIONS:** The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (March 20, 2000), 1233 Off. Gaz. Pat. Office (April 11, 2000).

**C-I-P NOT PERMITTED:** A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of the CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

**ACCESS TO PRIOR APPLICATION:** The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

- Enter the unentered amendment previously filed on \_\_\_\_\_ under 37 CFR 1.116 in the prior nonprovisional application.
- A preliminary amendment is enclosed.
- This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
  - DELETE** the following inventor(s) named in the prior nonprovisional application:  
\_\_\_\_\_
  - The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
- A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
- Information Disclosure Statement (IDS) is enclosed:
  - PTO-1449
  - Copies of IDS Citations

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take .4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231.

01/28/2003 CV0111 00000143 500815 09582964

01 FC:2006 375.00 CH

TECH CENTER 1600/2900  
JAN 29 2003

RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b) or (j))	12-20* =	0	X \$ =	\$
	INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))	3-3** =	0	=	
	MULTIPLE DEPENDENT CLAIMS (IF APPLICABLE) (37 CFR 1.16)			=	
				BASIC FEE (37 CFR 1.16)	750.00
				Total of above Calculations =	750.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.27).				375.00
* Reissue claims in excess of 20 and over original patent. ** Reissue Independent claims over original patent.				375.00	
TOTAL =					

6.  Small entity status: Applicant claims small entity status. See 37 CFR 1.27.

7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 50-0815.

- Fees required under 37 CFR 1.16.
- Fees required under 37 CFR 1.17.
- Fees required under 37 CFR 1.18.

8.  A check in the amount of \$ is enclosed.

9.  Payment by credit card. Form PTO-2038 is attached.

10.  Applicant requests suspension of action under 37 CFR 1.103(b) for a period of months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.

11.  New Attorney Docket Number, if desired  
[Prior application Attorney Docket Number will carry over to this CPA unless a new Attorney Docket Number has been provided herein.]

12. a.  Receipt For Facsimile Transmitted CPA (PTO/SB/29A)  
b.  Return Receipt Postcard (Should be specifically itemized, See MPEP 503)

13.  Other: \_\_\_\_\_

**NOTE:** The prior application's correspondence address will carry over to this CPA  
UNLESS a new correspondence address is provided below.

## 14. NEW CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	24353 (Insert Customer Number or Bar Code Label here)		<input type="checkbox"/> Correspondence address below
Name	BRET E. FIELD, Reg. No. 37,620 BOZICEVIC, FIELD & FRANCIS LLP		
Address	200 Middlefield Road, Suite 200		
City	Menlo Park	State	California
Country	U.S.A	Telephone	(650) 327-3400
			Fax

## 15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name	Bret E. Field
Signature	

Registration No. (Attorney/Agent)	37,620
Date	January 23, 2003

O P E R A T I O N S C 102  
JAN 23 2003  
PATENT & TRADEMARK OFFICE

RECEIVED

JAN 29 2003

CERTIFICATE OF MAILING

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EL79600148US

Typed or Printed Name

Donna Macedo

Signature

Donna Macedo

Date

1/23/03

1/17/03  
2/13/03

AMENDMENT UNDER  
37 C.F.R. §1.116

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Application Number	09/582,864
Title	Use of Serine Protease Inhibitors to Inhibit Pathophysiology and Neuropathology in a Host
Filing Date	July 6, 2000
First Named Inventor	Hoffman et al.
Examiner	R. Travers
Group Art	1617
Attorney Docket No.	THUR-001

Sir:

This amendment is responsive to the Final Rejection dated November 1, 2002 and is being submitted to accompany the CPA being filed herewith. In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested.

AMENDMENTS

IN THE CLAIMS

Please Cancel Claims 26-42.

Please enter the following new claims:

*Sub D*  
--43. A method of treating a host suffering from a condition characterized by an undesirable increase in synaptic responsiveness, said method comprising:

*C*  
administering to said host an amount of a serine protease inhibitor effective to treat said host for said condition.